Biotech firm Imunon's Q3 net loss widens

Overview

• US biotech firm's Q3 net loss widened yr/yr as operating expenses remained steady

• Company reduced outstanding debt by 43% via debt-for-equity exchange in Q3

• Imunon agreed to sell ThermoDox rights for potential milestone payments and royalties

Outlook

• Imunon expects enrollment in Phase 3 OVATION 3 study to finish by Q1 2029

• Company plans to advance IMNN-001 clinical development with support from National Cancer Institute

• Imunon aims to preserve financial flexibility through capital allocation and strategic partnerships

Result Drivers

• CLINICAL DEVELOPMENT COSTS - R&D and clinical costs for OVATION studies remained a primary expense driver, partially offset by lower manufacturing and supply costs

• OTHER LOSS - Co reported $0.3 mln in other loss, driving up net loss for Q3

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Imunon Inc is $13.00, about 1,705.3% above its November 11 closing price of $0.72

Reuters Recommended Reads

• Nov 9 - Coherus Oncology Q3 sales miss estimates

• Nov 10 - Cellectar Biosciences Q3 net loss widens on higher R&D costs

• Nov 9 - Perspective Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)